TECH OUTLOOK 8DECEMBER - 2021IN MY OPINIONLeading Global CDMO, PCI Has Further Expanded Its European Biotech Packaging Capabilities with Investment across Europe in Both the UK and Ireland FacilitiesBy Chris Dobbs, CEng., MIET, Head of Technical Engineering, PCI Pharma ServicesAt PCI, we are continuing to expand our European Biotech capabilities with a further $13.5m investment in the latest, state-of-the-art packaging technologies, complementing and mirroring recent investment in our US Biotech Center of Excellence at PCI's Philadelphia facility. The planned European investment will enhance our capacity to process the novel drug delivery systems required for biologic products, providing our customers with end-to-end packaging solutions to meet growing market demands. The packaging of biologics is highly complex, often requiring very specific packaging, storage and logistics solutions. An understanding of the potential risks to the product throughout the life-cycle is critical; as a result, using an expert partner able to take a product from the early stages of clinical development through a scalable process to commercial launch can be a cost-effective way of minimizing risk whilst expediting timelines.PCI has been delivering Biotech services in Europe for over 20 years and has developed a wealth of experience and expertise in managing such products. It is well recognized that worldwide forecasts for biologic drugs, including the increasing prevalence of biosimilars, has seen significant growth over the last decade, a trend set to continue over the coming years. As a result, this latest investment follows PCI's continued strategy of investing in technology and capacity today to offer the best possible solutions for our client's future demand.Another noteworthy trend is that of more personalized therapies and self-administration by Chris Dobbs CEng MIET
< Page 7 | Page 9 >